IASO Pharma Inc. Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2006)
Status: Acquired by Eli Lilly (1990)

Organization Overview

First Clinical Trial
2010
NCT01081964
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Nanjing IASO Biotherapeutics Co.,Ltd | Pacific Biotech | Shanghai IASO Biotechnology Co., Ltd

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autoimmune Diseases (Phase 1)

Autoimmune Diseases of the Nervous System (Phase 1)

Nervous System Diseases (Phase 1)

Neuromyelitis Optica (Phase 1)

Pneumonia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 9